Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations01:19

Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Underdiagnosed and Undertreated: Obesity and Its Cardiometabolic Burden in Swedish Clinical Practice-Insights From the AROS Database.

Diabetes, obesity & metabolism·2026
Same author

Severe α<sub>1</sub>-Antitrypsin Deficiency and Increased Risk of Gastrointestinal Diseases.

Mayo Clinic proceedings·2026
Same author

Uncontrolled Asthma and Severe COVID-19: A Prospective Bidirectional Risk Analysis.

Journal of asthma and allergy·2026
Same author

Estimating the societal cost of type 2 diabetes in Malmö, Sweden: a register-based cost analysis.

Frontiers in clinical diabetes and healthcare·2025
Same author

Airflow obstruction among young adults in Europe: a Chronic Airway Diseases Early Stratification (CADSET) collaboration with 48 612 individuals across eight population-based cohorts.

ERJ open research·2025
Same author

Beta-blockers in patients with heart failure with reduced ejection fraction and concomitant chronic obstructive pulmonary disease: Cardiovascular and respiratory outcomes.

European journal of heart failure·2025

Related Experiment Video

Updated: Jul 18, 2026

Alternative Therapy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Moving Cupping Along Meridians
04:03

Alternative Therapy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Moving Cupping Along Meridians

Published on: September 27, 2024

Cost differences for COPD with and without physician-diagnosis.

Sven-Arne Jansson1, Anne Lindberg, Asa Ericsson

  • 1The OLIN Studies, Department of Medicine, Sunderby Central Hospital of Norrbotten, SE-971 80 Luleå, Sweden. svenarne.jansson@holmsund.nu

COPD
|December 7, 2006
PubMed
Summary

Estimating the economic burden of Chronic Obstructive Pulmonary Disease (COPD) is challenging. This study reveals that undiagnosed COPD significantly contributes to total costs, suggesting register-based estimates underestimate the true economic impact.

More Related Videos

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

Related Experiment Videos

Last Updated: Jul 18, 2026

Alternative Therapy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Moving Cupping Along Meridians
04:03

Alternative Therapy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Moving Cupping Along Meridians

Published on: September 27, 2024

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

Area of Science:

  • Pulmonary Medicine
  • Health Economics

Background:

  • Previous cost of illness (COI) studies for Chronic Obstructive Pulmonary Disease (COPD) report varied estimates due to methodological differences.
  • Accurate COI data is crucial for resource allocation and healthcare policy development.

Purpose of the Study:

  • To compare register-based versus population-based estimates of COPD's economic burden.
  • To investigate cost differences between physician-diagnosed and undiagnosed COPD patients.

Main Methods:

  • A one-year study involving 212 randomly selected individuals with COPD from the Obstructive Lung Disease in Northern Sweden (OLIN) studies.
  • Four telephone interviews per subject to assess healthcare resource utilization and productivity losses.
  • Costs were calculated and extrapolated using estimated COPD prevalence in Sweden.

Main Results:

  • Average annual costs were SEK 18,252 for diagnosed COPD and SEK 9,327 for undiagnosed COPD.
  • Undiagnosed COPD patients represented approximately 40% of total COPD costs in Sweden.
  • A significant portion of individuals with COPD remain undiagnosed.

Conclusions:

  • The economic burden of COPD varies substantially between diagnosed and undiagnosed individuals.
  • Register-based studies likely underestimate the total economic impact of COPD.
  • Healthcare strategies should consider the substantial costs associated with undiagnosed COPD.